Masimo Shareholders OK $9.9B Merger Deal with Danaher

Masimo announced that its stockholders voted in favor of the proposal of a merger agreement by Masimo, Danaher Corp., and Mobius Merger Sub at its special meeting of stockholders held on May 1.

Under the merger agreement’s terms, at the effective time of the merger of Merger Sub with and into Masimo, each share of common stock and outstanding immediately prior to the effective time will be canceled and automatically converted into the right to receive $180 in cash, without interest.

The deal, which was first announced in February, is valued at $9.9 billion.

“We thank our shareholders for their strong support of this important milestone for Masimo,” said Masimo CEO Katie Szyman. “The Merger delivers compelling value and positions Masimo for continued global growth as an independent operating company within Danaher’s Diagnostics segment. We look forward to completing this process and, together with Danaher, continuing our mission of developing innovative technologies that empower clinicians to transform patient care.”

The merger, which is subject to fulfillment of customary closing conditions, is expected to close in 2026. Masimo will become a standalone business unit and brand in Danaher’s Diagnostics segment and will operate autonomously, strengthening its offering in acute care settings.

The company develops and produces a variety of monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions.